$695 | Single User
$1395 | Global License

Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 01 Jul 2013 | 51 | In Stock

Introduction

Scope


The recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Remicade in Europe has gone a long way to validate the regulatory pathway for biosimilar monoclonal antibody products in the region.


Most significantly, the biosimilar product in question – which is to be sold by Celltrion and Hospira under the brand names Remsima and Inflectra, respectively – has been recommended for approval in each of the six indications for which branded Remicade is approved, despite Celltrion producing bioequivalence data in just two of these indications; ankylosing spondylitis and rheumatoid arthritis.


Whether European regulatory authorities rule similarly on indication extrapolation for biosimilar versions of other products remains to be seen. However, this process of approval may play a significant role in how the product is perceived by physicians and how it performs commercially.


The expected full approval of Celltrion and Hospira's product later in Q3 will shift some focus on to how biosimilar monoclonal antibodies actually perform on the market. Initial launch – likely from 2014 onwards – will occur in a number of smaller European markets, with exclusivity on Remicade not expected to expire in the region's larger markets until 2015.


Nevertheless, gauging the stance of rheumatologists and gastroenterologists towards the prospect of biosimilar Remicade in the largest European markets remains an intriguing task, particularly as analysts appear to have no clear view on how the product is likely to perform once launched.


The general view from analysts is that recommendation – and likely approval of a full label based on indication extrapolation – is a positive development for biosimilar developers and will add some incremental pressure on branded players. The key question remains, however; will physicians prescribe biosimilar Remicade once it becomes available?


Puchase Reasons


This week's Physician Views poll asks rheumatologists and gastroenterologists based in France, Germany, Italy, Spain and the UK:


  • How they rate their understanding of the potential differences between biosimilars and reference biologics?

  • If available today, to what percentage of new patients they would prescribe a biosimilar Remicade product?

  • How comfortable they would be in prescribing a biosimilar Remicade product for the treatment of indications for which it has not been clinically tested directly?

  • To what extent they anticipate that payers will dictate their future usage of biosimilar Remicade and other biosimilar anti-TNF products?

  • What information/materials/support supplied by a biosimilar manufacturer would have the most positive impact on their usage of biosimilar products?
  • Table of Contents
    for Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    51 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Which diabetes company does the best marketing job? What is key for companies launching products?
    ScopeThe importance of marketing is increasingly coming to the fore as diabetes-focused companies ba...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...